Mechanisms of nephrotoxicity

Transplantation

Volumn 69, Issue 12 SUPPL., 2000, Pages

  Campistol, Josep M ^a   Sacks, Steven H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; ENDOTHELIN 1; NITRIC OXIDE; PROSTAGLANDIN; TACROLIMUS; THROMBOXANE;

CELL DAMAGE; CONFERENCE PAPER; DOSE RESPONSE; DRUG WITHDRAWAL; GLOMERULOSCLEROSIS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; NEPHROTOXICITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE; VASOCONSTRICTION;

EID: 0343526823     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006271-00002     Document Type: Conference Paper

References (72)

1. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34(11): 515-519.
2. Beers MH, Berkow R, eds. Transplantation. In: The Merck Manual of Diagnosis and Therapy 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999: 1067-1083.
3. Perico N, Remuzzi G. Prevention of transplant rejection. Current treatment guidelines and future developments. Drugs 1997; 54(4): 533-570.
4. Diasio RB, LoBuglio AF. Immunomodulators: immunosuppressive agents and immunostimulants. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics 9th ed. New York, NY: McGraw-Hill Companies, Inc; 1996: 1291-1308.
5. Mihatsch MJ, Kyo M, Morozumi K, et al. The side effects of cyclosporine-A and tacrolimus. Clin Nephrol 1998; 49(6): 356-363.
6. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13(3): 209-220.
7. Aramburu J, Yaffe MB, López-Rodríguez C, et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporine A. Science 1999; 285: 2129-2133.
8. Hamilton GS, Steiner JP. Immunophilins: beyond immunosuppression. J Med Chem 1998; 41(26): 5119-5143.
9. Lui J, Albers MW, Wandless TJ, et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992; 31(16): 3896-3901.
10. Zhu J, McKeon F. NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Nature 1999; 398(6724): 256-260.
11. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991; 352(6338): 803-807.
12. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31(5): 335-340.
13. Franceschini N, Alpers CE, Bennett WM, Andoh TF. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 1998; 32(2): 247-253.
14. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997; 17(1): 34-45.
15. Perico N, Benigni A, Bosco E, et al. Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25 (suppl 1): S83-S38.
16. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44(1): 135-141.
17. Zoja C, Furci L, Ghilardi F, et al. Cyclosporine-induced endothelial cell injury. Lab Invest 1986; 55(4): 455-462.
18. Antonovych TT, Sabnis SG, Austin HA, et al. Cyclosporine A-induced arteriolopathy. Transplant Proc 1988; 20(suppl 3): 951-958.
19. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(suppl 3): 759-771
20. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33(2): 590-600.
21. Olyaei AJ, de Matos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf 1999; 21(6): 471-488.
22. Ong ACM, Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int 1994; 45: 345-351.
23. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674-685.
24. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29(1): 2-26.
25. Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27(1): 151-161.
26. Avdonin PV, Cotter-Maire F, Afanasjeva GV, et al. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55(6): 2407-2414.
27. Marsen TA, Weber F, Egink G, Suckau G, Baldamus CA. Cyclosporine A induces prepro endothelin-1 gene transcription in human endothelial cells. Eur J Pharmacol 1999; 379(1): 97-106.
28. Grekas D, Bamichas G, Karamouzis M, et al. Plasma endothelin in cyclosporine A-treated renal transplant patients. Transplant Proc 1999; 31(3): 1703-1705.
29. Cavarape A, Endlich K, Feletto F, et al. Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction-mediated vasoconstriction in rats. Kidney Int 1998; 53(4): 963-969.
30. Brooks DP, Contino LC. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670. Eur J Pharmacol 1995; 294: 571-576.
31. Bloom ITM, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 1993; 114: 480-488.
32. Hutchinson IV. An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. Curr Opin Nephrol Hypertens 1998; 7(6): 665-671.
33. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors link endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 1995; 60(1): 89-95.
34. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28(5): 767-774.
35. Murray BM, Paller MS. Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol 1986; 25(suppl 1): S37-S39.
36. Xue H, Bukoski RD, McCarron DA, Bennett WM. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 1987; 43(5): 715-718.
37. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-699.
38. Golub MS, Lustig S, Berger ME, Lee DBN. Altered vascular responses in cyclosporine-treated rats. Transplantation 1989; 48(1): 116-118.
39. Rossi NF, Churchill PC, McDonald, Ellis VR. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat. J Pharmacol Exp Ther 1989; 250(3): 896-901.
40. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad USA 1985; 82(223): 8222-8226.
41. Coffman TM, Carr DR, Yarger WE, Klotman PE. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 1987; 43(2): 282-285.
42. Rossini M, Belloni A, Remuzzi G, Perico N. Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. Biochem Pharmacol 1989; 38(13): 2153-2157.
43. Kim YJ, Park YH, Moon HK. Reduction of chronic cyclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046. Kidney Blood Press Res 1997; 20(1): 38-43.
44. Grieve EM, Hawksworth GM, Simpson JG, Whiting PH. The reversal of experimental cyclosporine A nephrotoxicity by thromboxane synthetase inhibition. Biochem Pharmacol 1993; 45(6): 1351-1354.
45. Gladue RP, Newborg MF. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats. Transplantation 1991; 52(5): 837-841.
46. Petric R, Freeman D, Wallace C, et al. Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis. Transplantation 1990; 50(4): 558-563.
47. Perico N, Rossini M, Imberti O, et al. Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 1992; 2(9): 1398-1404.
48. Spurney RF, Mayros SD, Collins D, et al. Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats. Prostaglandins 1990; 39(2): 135-146.
49. Smith SR, Kubacki VB, Rakhit A, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation 1993; 56(6): 1422-1426.
50. Smith SR, Creech EA, Schaffer AV, et al. Effects of thromboxane synthase inhibition with CGS13080 in human cyclosporine nephrotoxicity. Kidney Int 1992; 41(1): 199-205.
51. Navarro-Antolin J, Rey-Campos J, Lamas S. Transcriptional induction of endothelial nitric oxide gene by cyclosporine A. A role for activator protein-1. J Biol Chem 2000; 275(5): 3075-3080.
52. Stroes ES, Luscher TF, de Groot FG, et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29(2): 570-75.
53. Bracht C, Yan XW, LaRocca HP, et al. Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension. J Hypertens 1999; 17(3): 357-63.
54. Yang CW, Kim YS, Kim J, et al. Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats. Exp Nephrol 1998; 6(1): 50-56.
55. Andoh TF, Gardner MP, Bennett WM. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997; 64(9): 1236-1240.
56. Bloom IT, Bentley FR, Spain DA, Garrison RN. An experimental study of altered nitric oxide metabolism of cyclosporine-induced renal vasoconstriction. Br J Surg 1995; 82(2): 195-198.
57. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporine nephrotoxicity. Kidney Int 1994; 46(3): 773-779.
58. Lee J, Kim SW, Kook H, et al. Effects of L-arginine on cyclosporine-induced alterations of vascular NO/cGMP generation. Nephrol Dial Transplant 1999; 14(11): 2634-2638.
59. Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 1997; 65(suppl): 678S-681S.
60. Mervaala E, Lassila M, Vaskonen T, et al. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet. Blood Press 1999; 8(1): 49-56.
61. Perico N, Benigni A, Bosco E, et al. Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25 (suppl 1): S83-S88.
62. Johnson DW, Saunders HJ, Johnson FJ, et al. Fibrogenic effects of cyclosporine A on the tubulointerstitium: role of cytokines and growth factors. Exp Nephrol 1999; 7(5-6): 470-478.
63. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-b1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49(4): 1141-1151.
64. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-b1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-673.
65. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-b1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56(2): 714-719.
66. Ong ACM, Fine LG. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: implications for human renal disease progression. Am J Kidney Dis 1994; 23(2): 205-209.
67. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64(12): 1829-1837.
68. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196.
69. Young BA, Burdmann EA, Johnson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439-448.
70. Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147-2159.
71. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53(4): 897-908.
72. Del Moral RG, Olmo A, Osuna A, et al. Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc 1998; 30(5): 2014-2016.